Four months after first intranasal flunks influenza test, Revelation's second-gen asset misses on efficacy

Revelation Biosciences had big plans for 2022 after going public via a SPAC in January and also raising $7.7 million in PIPE financing later that …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Four months af­ter first in­tranasal flunks in­fluen­za test, Rev­e­la­tion's sec­ond-gen as­set miss­es on ef­fi­ca­cy